Please login to the form below

Not currently logged in
Email:
Password:

fluticasone furoate

This page shows the latest fluticasone furoate news and features for those working in and with pharma, biotech and healthcare.

GSK’s Advair Diskus faces first generic in US

GSK’s Advair Diskus faces first generic in US

It has also given GSK a bit more time to advance its three-drug COPD product Trelegy (fluticasone furoate/umeclidinium/vilanterol) as well as other new respiratory drugs – although some analysts

Latest news

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate) ... GSK has high hopes for three-drug

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    triple – based on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate – in the US and Europe last year.

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    Anoro is one of the drugs GSK is hoping will help replace its COPD blockbuster Seretide/Advair (salmeterol/fluticasone propionate), which has lost patent protection and seen revenues slide in recent ... GSK’s Trelegy (umeclidinium/vilanterol/

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    The new US label means Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can be used in a broader population of chronic obstructive pulmonary disease (COPD) patients with difficulty breathing or who see ... GSK claims Trelegy has made the

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year. ... salmeterol and fluticasone propionate) that was a $7bn product at its peak but has seen sales slip of late, coming in at $3.3bn in the first nine

More from news
Approximately 5 fully matching, plus 33 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics